[急性非淋巴细胞白血病中DCMP疗法（2M - 80）的治疗结果——残留白血病细胞与缓解期之间的关系]
[Therapeutic results of DCMP therapy (2M-80) in acute non-lymphocytic leukemia--the relationship between the residual leukemic cells and duration of remission].
作者信息
Moriyama Y, Urushiyama M, Ohnishi M, Koyama S, Hirosawa H, Hanano M, Fuse I, Takai K, Nagayama R, Fujiwara M, Kishi K, Takahashi M, Koike T, Sakai C, Kashimura M, Miura R, Aoyagi A, Sanada M, Hattori A, Shibata A, Shinada S
出版信息
Gan To Kagaku Ryoho. 1982 Sep;9(9):1549-54.
In this study the duration of complete remission by daunomycin, cytosine arabinoside (Ara-C), 6MP and prednisolone (DCMP) therapy using a large dose of Ara-C (200 mg) (protocol 2M-80) was compared with that of DCMP therapy with a low dose of Ara-C (80-160 mg) in acute non-lymphocytic leukemia (ANLL). In protocol 2M-80, the chemotherapy was continued until leukemic blasts in marrow were attained below 3%. Complete remission was induced in about 80% of ANLL patients in both chemotherapies. However, the duration of remission in protocol 2M-80 appeared to be much longer than that of DCMP therapy with a low, dose of Ara-C. This difference was dependent not on the consolidation and maintenance therapy, but on the total dose of Ara-C used and leukemic blasts left in marrow at the end of chemotherapy. This suggests that it is important to reduce leukemic blasts in marrow as low as possible by induction chemotherapy to obtain a long-term remission in ANLL.
在本研究中，比较了在急性非淋巴细胞白血病（ANLL）中，使用大剂量阿糖胞苷（200mg）的柔红霉素、阿糖胞苷（Ara-C）、6-巯基嘌呤（6MP）和泼尼松龙（DCMP）疗法（方案2M - 80）与使用低剂量阿糖胞苷（80 - 160mg）的DCMP疗法的完全缓解持续时间。在方案2M - 80中，化疗持续进行，直到骨髓中的白血病原始细胞比例降至3%以下。两种化疗方法在约80%的ANLL患者中诱导出完全缓解。然而，方案2M - 80的缓解持续时间似乎比低剂量阿糖胞苷的DCMP疗法长得多。这种差异并不取决于巩固和维持治疗，而是取决于所使用的阿糖胞苷总剂量以及化疗结束时骨髓中残留的白血病原始细胞数量。这表明，通过诱导化疗将骨髓中的白血病原始细胞尽可能降低对于获得ANLL的长期缓解很重要。
Zotero 插件